Responses
Poster
IGCS20_1113
138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)
Compose a Response to This Article
Other responses
No responses have been published for this article.